EcoDrugPlus

Neuronal Acetylcholine Receptor Subunit Beta-2-Like

Ensembl ID : ENSCING00000002138
Gene Symbol: NACHR
4 Cross references
274 Possible Orthologues:

Nicotinic Acetylcholine Receptor Subunit

Ensembl ID : ENSCING00000002441
Gene Symbol: NACHR
4 Cross references
207 Possible Orthologues:

Nuclear Receptor

Ensembl ID : ENSCING00000006945
Gene Symbol: RAR
4 Cross references
453 Possible Orthologues:

Proteasome Subunit Alpha Type-1-Like

Ensembl ID : ENSCING00000005222
Gene Symbol: LOC100183036
4 Cross references
285 Possible Orthologues:

Proteasome Subunit Alpha Type-2-Like

Ensembl ID : ENSCING00000023728
Gene Symbol: LOC100179585
4 Cross references
293 Possible Orthologues:

Proteasome Subunit Alpha Type-3-Like

Ensembl ID : ENSCING00000007946
Gene Symbol: LOC100177476
4 Cross references
252 Possible Orthologues:

Proteasome Subunit Beta Type-2-Like

Ensembl ID : ENSCING00000024358
Gene Symbol: LOC100179460
4 Cross references
223 Possible Orthologues:

Proteasome Subunit Beta Type-3-Like

Ensembl ID : ENSCING00000009575
Gene Symbol: LOC113474124
4 Cross references
261 Possible Orthologues:

Protein Arginine N-Methyltransferase 5

Ensembl ID : ENSCING00000008098
Gene Symbol: LOC100186564
4 Cross references
198 Possible Orthologues:

Protein Farnesyltransferase Subunit Beta

Ensembl ID : ENSCING00000005433
Gene Symbol: LOC100182889
4 Cross references
211 Possible Orthologues:

Putative N-Acetylated-Alpha-Linked Acidic Dipeptidase

Ensembl ID : ENSCING00000021112
Gene Symbol: LOC100180761
4 Cross references
332 Possible Orthologues:

R35a Protein

Ensembl ID : ENSCING00000024743
Gene Symbol: R35A
4 Cross references
514 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).